Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures
Public ClinicalTrials.gov record NCT03288129. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will assess the retention rate of perampanel when given as monotherapy or first adjunctive therapy in participants with partial-onset seizures or primary generalized tonic clonic seizures. The study consists of 4 periods: a Screening Period (to start no earlier than 6 weeks before the first dose of study drug), a Titration Period (up to 13 weeks), a Maintenance Period (39 weeks), and a Follow-Up Period (4 weeks).
Study identification
- NCT ID
- NCT03288129
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 54 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 4 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 23, 2017 (Actual)
- Primary completion
- Apr 27, 2021 (Actual)
- Completion
- Apr 27, 2021 (Actual)
- Last update posted
- May 16, 2022
2017 – 2021
United States locations
- U.S. sites
- 24
- U.S. states
- 17
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham | Birmingham | Alabama | 35294 | — |
| Barrow Neurological Institute | Phoenix | Arizona | 85013 | — |
| Arkansas Epilepsy Program | Little Rock | Arkansas | 72205 | — |
| UCSD Epilepsy Center | La Jolla | California | 92393 | — |
| Stanford Medical Center | Palo Alto | California | 94304 | — |
| UC Davis Medical Center | Sacramento | California | 95817 | — |
| Baptist Health, Nemours Children's Specialty Care | Jacksonville | Florida | 32207 | — |
| RUSH University Medical Center | Chicago | Illinois | 60612 | — |
| University of Kentucky | Lexington | Kentucky | 40536 | — |
| Johns Hopkins Medicine | Baltimore | Maryland | 21287 | — |
| Mid-Atlantic Epilepsy and Sleep Center | Bethesda | Maryland | 20817 | — |
| Tufts Medical Center | Boston | Massachusetts | 02111 | — |
| The Regents of The University of Michigan | Ann Arbor | Michigan | 48109 | — |
| Michigan State University | East Lansing | Michigan | 48824 | — |
| Minneapolis Clinic of Neurology | Golden Valley | Minnesota | 55442 | — |
| JFK Medical Center | Edison | New Jersey | 08820 | — |
| Northeast Regional Epilepsy Group | Hackensack | New Jersey | 07601 | — |
| UNM Health Providers | Albuquerque | New Mexico | 87106 | — |
| Mount Sinai Medical Center | New York | New York | 10016 | — |
| Duke Neurology | Durham | North Carolina | 27710 | — |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | 44106 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| UT Southwestern Medical Center | Dallas | Texas | 75390 | — |
| Children's Hospital of San Antonio | San Antonio | Texas | 78207 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03288129, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 16, 2022 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03288129 live on ClinicalTrials.gov.